Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical activity with a Bruton tyrosine kinase (BTK) inhibito...

Full description

Bibliographic Details
Main Authors: Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir
Format: Article
Language:English
Published: SAGE Publishing 2023-05-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207231173489

Internet

https://doi.org/10.1177/20406207231173489

Similar Items